A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line

Kantarjian, 2002, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med, 346, 645, 10.1056/NEJMoa011573 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Takeuchi, 2012, RET, ROS1 and ALK fusions in lung cancer, Nat Med, 18, 378, 10.1038/nm.2658 Kohno, 2012, KIF5B-RET fusions in lung adenocarcinoma, Nat Med, 18, 375, 10.1038/nm.2644 Lipson, 2012, Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies, Nat Med, 18, 382, 10.1038/nm.2673 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3 Seto, 2013, CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study, Lancet Oncol, 14, 590, 10.1016/S1470-2045(13)70142-6 Ou, 2013, Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC), J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.8032 Drilon, 2013, Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas, Cancer Discov, 3, 630, 10.1158/2159-8290.CD-13-0035 Stephens, 2011, Massive genomic rearrangement acquired in a single catastrophic event during cancer development, Cell, 144, 27, 10.1016/j.cell.2010.11.055 Molenaar, 2012, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes, Nature, 483, 589, 10.1038/nature10910 Magrangeas, 2011, Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients, Blood, 118, 675, 10.1182/blood-2011-03-344069 Kloosterman, 2011, Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer, Genome Biol, 12, R103, 10.1186/gb-2011-12-10-r103 Rausch, 2012, Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations, Cell, 148, 59, 10.1016/j.cell.2011.12.013 Northcott, 2012, Subgroup-specific structural variation across 1,000 medulloblastoma genomes, Nature, 488, 49, 10.1038/nature11327 Sakamoto, 2011, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant, Cancer Cell, 19, 679, 10.1016/j.ccr.2011.04.004 Kitada, 2012, Coamplification of multiple regions of chromosome 2, including MYCN, in a single patchwork amplicon in cancer cell lines, Cytogenet Genome Res, 136, 30, 10.1159/000334349 Johansson, 2004, Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping, Ann Diagn Pathol, 8, 259, 10.1016/j.anndiagpath.2004.07.001 Bishop, 2010, Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma, Hum Pathol, 41, 20, 10.1016/j.humpath.2009.06.014 Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, 3, 75ra26, 10.1126/scitranslmed.3002003 Devarajan, 2012, Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells, Int J Cancer, 131, 1023, 10.1002/ijc.26493 Bishop, 2012, p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma, Mod Pathol, 25, 405, 10.1038/modpathol.2011.173 Kitada, 2011, Chromosome-specific segmentation revealed by structural analysis of individually isolated chromosomes, Genes Chromosomes Cancer, 50, 217 Katayama, 2011, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK, Proc Natl Acad Sci U S A, 108, 7535, 10.1073/pnas.1019559108 Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers, Sci Transl Med, 4, 120ra17, 10.1126/scitranslmed.3003316 Kuromitsu, 2011, Anti-tumor activity of ASP3026, –A novel and selective ALK inhibitor, Cancer Res, 71, 10.1158/1538-7445.AM2011-2821 Wu, 2012, Poly-gene fusion transcripts and chromothripsis in prostate cancer, Genes Chromosomes Cancer, 51, 1144, 10.1002/gcc.21999 Cazes, 2013, Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma, Cancer Res, 73, 195, 10.1158/0008-5472.CAN-12-1242 Boland, 2009, Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas, Hum Pathol, 40, 1152, 10.1016/j.humpath.2009.01.012 Gainor, 2013, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer, Clin Cancer Res, 19, 4273, 10.1158/1078-0432.CCR-13-0318 Rossi, 2003, Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases, Am J Surg Pathol, 27, 311, 10.1097/00000478-200303000-00004 Tanizaki, 2012, Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells, Br J Cancer, 106, 763, 10.1038/bjc.2011.586 Koivunen, 2008, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer, Clin Cancer Res, 14, 4275, 10.1158/1078-0432.CCR-08-0168